Skip to content

Effects of Intranasal Oxytocin on Functional Brain Network in Resting-state and Tasks

Effects of Intranasal Oxytocin on Male's Functional Brain Network in Resting-state and Tasks

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03428906
Enrollment
34
Registered
2018-02-12
Start date
2016-05-24
Completion date
2017-09-12
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

intranasal oxytocin, functional brain network, multiple tasks, resting state

Brief summary

To investigate whether and how intranasal oxytocin of 8IU treatment will alter the topology of functional brain network in resting-state and multiple tasks in healthy males.

Detailed description

In a randomized, double-blind, cross-over, placebo controlled design, healthy male volunteers receive intranasal oxytocin or placebo prior to functional magnetic resonance imaging.Subjects will then go through a decision making task, a emotion judgement task and an eight-minute resting-state scan in MRI scanner to investigate whether and how intranasal oxytocin alter the topology of functional brain network in resting-state and multiple tasks in healthy males. State anxiety and mood are measured before and after experiment as covariates to be controlled.

Interventions

DRUGOxytocin

intranasally administrated

DRUGPlacebo

intranasally administrated

Sponsors

Beijing Normal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Intervention model description

The study utilized a randomized, double-blind, PBO controlled, within-subject design, in which each participant was tested under two acute treatment conditions separated by at least 1 wk wash-out period.

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy subjects without past or current psychiatric or neurological disorders

Exclusion criteria

* with MRI Contraindications

Design outcomes

Primary

MeasureTime frameDescription
Functional network organization alterations in brain under resting state fMRI after drug administration70~85 minutes after drug administrationUsing seed-based and network level functional connectivity analysis, as well as graph theory analysis , functional network organization in brain under eight minutes resting state will be detected and compared between oxytocin and placebo group.
Behavior,brain activities and representation patterns in the emotional judgement task after drug administration60~75 minutes after drug administrationFriend or Foe Task is used to measure the verbal versus nonverbal emotional judgement of subjects. Both the response of subjects and the brain activity are recorded in the task. How oxytocin influences the relationship between subjects' behavior and representation pattern of emotional judgement will be investigated through RSA(representation similarity analysis) of brain pattern.
Behavior, dynamics brain activities and networks in the model-based decision making task after drug administration35~60 minutes after drug administrationTwo-Stage Decision Making Task is used to measure the model-based and model-free decision making process of subjects. The degree of model-based will be calculated by Computational modelling of Subjects' decision making process, and entering as modulation parameter in the OT effect on dynamic brain seed-based and network-based connectivity pattern.
Relationship of functional network organization in brain across resting state and task-based fMRI after drug administration60~85 minutes after drug administrationThe functional brain activity in resting state, emotional judgement and decision making task will be compared. Both the functional segregation and integration will be measured using graph theory and network connectivity analysis to discover the OT effect on brain network organization across multiple cognitive states.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026